Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

Cumberbatch, Marcus; Foerster, Beat; Catto, James W.F.; Kamat, Ashish M.; Kassouf, Wassim; Jubber, Ibrahim; Shariat, Shahrokh F.; Sylvester, Richard; Gontero, Paolo

doi:10.1016/j.eururo.2018.02.014

Cited by 242 publications

(208 citation statements)

References 48 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…In addition, for TURBT, the presence or absence of detrusor muscle in the specimen determines the quality of the biopsy or resection, and this depends on surgeon experience . A recent systematic review revealed that, after repeat TURBT, upstaging to MIBC has been reported in up to 32% of patients who had NMIBC diagnosed by initial TURBT . Large‐series studies on cystectomy have also shown a risk of a clinical understaging error in NMIBC diagnosis of 34% to 53% .…”

Section: Discussionmentioning

confidence: 99%

“…9 A recent systematic review revealed that, after repeat TURBT, upstaging to MIBC has been reported in up to 32% of patients who had NMIBC diagnosed by initial TURBT. 38 Large-series studies on cystectomy have also shown a risk of a clinical understaging error in NMIBC diagnosis of 34% to 53%. [6][7][8] Even within the same pathologic T stage, patients who were clinically understaged were at significantly higher risk for disease recurrence and cancer-specific death than patients who had correct clinical staging.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach

Zheng

Kong

et al. 2019

Cancer

View full text Add to dashboard Cite

Background Bladder cancer (BCa) can be divided into muscle‐invasive BCa (MIBC) and non−muscle‐invasive BCa (NMIBC). Whether the tumor infiltrates the detrusor muscle is a critical determinant of disease management in patients with BCa. However, the current preoperative diagnostic accuracy of muscular invasiveness is less than satisfactory. The authors report a radiomic‐clinical nomogram for the individualized preoperative differentiation of MIBC from NMIBC. Methods In total, 2602 radiomics features were extracted from whole bladder tumors and the basal part of the lesions on T2‐weighted magnetic resonance imaging. Then, a radiomics signature was constructed using the least absolute shrinkage and selection operator algorithm in the training set (n = 130). Furthermore, a radiomic‐clinical nomogram was developed incorporating the radiomics signature and selected clinical predictors based on a multivariable logistic regression analysis. The performance of the nomogram (discrimination, calibration, and clinical usefulness) was assessed and validated in an independent validation set (n = 69). Results The radiomics signature, consisting of 23 selected features, showed good discrimination in the training and validation sets (area under the curve [AUC], 0.913 and 0.874, respectively). Incorporating the radiomics signature and magnetic resonance imaging‐determined tumor size, the radiomic‐clinical nomogram showed favorable calibration and discrimination in the training set with an AUC of 0.922, which was confirmed in the validation set (AUC, 0.876). Decision curve analysis and net reclassification improvement and integrated discrimination improvement indices (net reclassification improvement, 0.338, integrated discrimination improvement, 0.385) demonstrated the clinical usefulness of the nomogram. Conclusions The proposed noninvasive radiomic‐clinical nomogram can increase the accuracy of preoperatively discriminating MIBC from NMIBC, which may aid in clinical decision making and improve patient prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach

Zheng

Kong

et al. 2019

Cancer

View full text Add to dashboard Cite

show abstract

“…In fact, current guidelines recommend a second TURBT in patients diagnosed with high-risk NMIBC or in cases of T1 bladder cancer without muscle in the specimen [4]. Repeating TURBT in these patients allows urologists to find patients where a muscle invasion was misdiagnosed or to find residual NMIBC tumours [8]. However, this procedure is related to high costs, risk of complications and could potentially be avoided in a high percentage of patients where no further tumour would be diagnosed.…”

Section: The Effectiveness Of Mpmri In Avoiding Second Turbt In High-mentioning

confidence: 99%

The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review

Carando

Afferi

Marra

et al. 2020

Arab Journal of Urology

View full text Add to dashboard Cite

2020) The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review, ABSTRACT Objective: To evaluate the role of the Vesical Imaging-Reporting and Data System (VI-RADS) score in the diagnostic pathway of bladder cancer. Methods: A systemic search of the contemporary literature was performed in December 2019 using the Medical Literature Analysis and Retrieval System Online (MEDLINE), the Excerpta Medica dataBASE (EMBASE), and Web of Science databases focussing on all available articles on VI-RADS.Results: Overall, six of 15 articles were included. All the available articles evaluated the ability of radiologists to use the VI-RADS score for discriminating non-muscle-invasive bladder cancer (NMIBC) from muscle-invasive bladder cancer (MIBC). Considering a cut-off VI-RADS score of >2, the sensitivity, specificity, positive (PPV) and negative predictive value (NPV) were 78-91.9%, 85-91%.1, 69-78%, and 88-97.1%, respectively. Considering a VI-RADS score cut-off of >3, the sensitivity, specificity, PPV and NPV were 77-94.6%, 43.9-96.5%, 51.6-86%, and 63.7-93%, respectively. Good interobserver agreement was demonstrated in the evaluated studies with a κ score of 0.73-0.89. Only one study evaluated the utility of VI-RADS in determining the presence of MIBC in patients treated with transurethral resection of the bladder diagnosed with high-grade T1 before the second transurethral resection using a VI-RADS score cut-off of >2; the sensitivity, specificity, PPV and NPV were 85%, 93.6%, 74.5%, and 96.6%, respectively. Conclusion: The VI-RADS score, using multiparametric magnetic resonance imaging, showed excellent results in discriminating MIBC from NMIBC. Preliminary results have been reported for its use in patients with high-grade T1 bladder cancer. These results need to be validated in high-quality real-world settings.Abbreviations: DCE: dynamic contrast enhancement; DWI: diffusion-weighted imaging; (N) MIBC: (non-)muscle-invasive bladder cancer; mpMRI: multiparametric MRI; TURBT: transurethral resection of bladder tumour; (N)(P)PV: (negative) (positive) predictive value; SC: structural category; T2W: T2-weighted; VI-RADS: vesical imaging-reporting and data system ARTICLE HISTORY

show abstract

“…Lastly, participants indicated that they had the impression of inspecting on average 91% of the bladder's surface during cystoscopy. This percentage could be further optimized in order to prevent the high residual tumor rates observed after initial TURB in Ta (67%) and T1 tumors (71%) [24]. These data are proof of concept that technology could help decrease the time required to re-acquaint a clinician with the medical history of patients, assist in data summarization, and ensure greater documentation accuracy for optimal patient care and surveillance.…”

Section: Discussionmentioning

confidence: 90%

Current Standards in the Endoscopic Management of Bladder Cancer: A Survey Evaluation among Urologists in German-Speaking Countries

et al. 2020

View full text Add to dashboard Cite

Introduction: To assess the current diagnostic, treatment, and documentation strategies for bladder cancer (BC) in German-speaking countries. Materials and Methods: A 14-item web-based survey was distributed among members of the German, Austrian, and Swiss Associations of Urology, addressing physicians who perform cystoscopies and transurethral resection of bladder tumors (TURB). Results: The survey was responded to by 308 of 5,564 urologists with a mean age of 49.5 years (response rate: 5.5%). The majority of participants (57.3%) practice in an outpatient setting. White light cystoscopy only is used by 60.2%, with additional photody-namic diagnosis and narrow band imaging by 36.8 and 12.5%, respectively. Endoscopic findings are documented in written form by 93.5%, followed by image capture (33.7%) and a central data archive (20.8%). Inpatient hospital urologists document cystoscopic findings by freehand drawing (21.4 vs. 11.4%, p = 0.017), and with a fixed bladder scheme (31.3 vs. 7.4%, < 0.05) significantly more frequently. Cystoscopic findings are mainly conveyed to other health professionals in written form (77.4%), and significantly more often by inpatient urologists (p < 0.05). Conclusions: Significant differences exist in the approach to documenting and communicating cystoscopic BC findings. Accurate graphic documentation of lesions, visualization of the mucosa's totality, and meticulous consultation of previous surgical reports require improvements to reduce recurrence and progression rates.

show abstract

Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

Cited by 242 publications

References 48 publications

Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach

Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach

The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review

Current Standards in the Endoscopic Management of Bladder Cancer: A Survey Evaluation among Urologists in German-Speaking Countries

Contact Info

Product

Resources

About